Medicinal Bioconvergence Research Center
Records under this name other than the patents Medicinal Bioconvergence Research Center holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Back to Medicinal Bioconvergence Research Center
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,573,907 | Novel 2, 4-Pyrimidine Derivatives and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,677,806 | Composition for Diagnosing Follicular Thyroid Carcinoma Using Expression Level of Aminoacyl-Trna Synthetase-Related Protein and Method for Detecting Diagnostic Marker Formerly held In force · High confidence | In force | High confidence | |
| US 11,207,389 | Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-tRNA synthetase as an active ingredient Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,378,572 | Therapeutic agent for immune cell migration-caused disease and method for screening same Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,965,038 | Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,685,791 | Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,130,611 | Use of Benzo-Heterocycle Derivatives for Preventing and Treating Cancer or for Inhibiting Cancer Metastasis Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 11,442,057 | Method for Screening Anticancer Agent Inhibiting Binding of AIMP2-DX2 and HSP70 Lapsed on the fee record Ended Sep 13, 2026 · High confidence | Lapsed on the fee record | Ended Sep 13, 2026 | High confidence |
| US 11,360,093 | Colorectal cancer diagnostic composition, and method for detecting diagnostic marker Lapsed on the fee record Ended Jun 14, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2026 | USPTO record |
| US 7,459,529 | AIMP2-DX2 and Its Uses Term ended Term ended Nov 1, 2025 · High confidence | Term ended | Term ended Nov 1, 2025 | High confidence |